Details of the Drug

General Information of Drug (ID: DMCA9QP)

Drug Name
Papaverine
Synonyms
papaverine; Papaverin; Papanerine; Robaxapap; 58-74-2; Papanerin; Pavabid; Papaverina; Pavatym; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline; Cerespan; Papaverine [BAN]; Pavacot; Papaverina [Italian]; 6,7-Dimethoxy-1-veratrylisoquinoline; Papaverine Hcl; NSC 136630; UNII-DAA13NKG2Q; Isoquinoline, 6,7-dimethoxy-1-veratryl-; S-M-R; Papaverine (BAN); Pamelon; Chlorhydrate de papaverine; Qua bid; 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline; 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline; Alapav; Cardiospan; Cardoverina; Ceraspan; Cerebid; Delapav; Dilaves; Dispamil; Drapavel; Durapav; Dynovas; Forpavin; Genabid; Mesotina; Myobid; Pameion; Panergon; Papacon; Papalease; Papaversan; Pavacap; Pavacels; Pavacen; Pavagen; Pavarine; Pavatest; Pavatine; Paverolan; Paveron; Pavnell; Vasal; PAP H; Papavarine chlorhydrate; Papaverine chlorohydrate; Papaverine monohydrochloride; Papaverinium chloride; Pavabid Hp; RS 47; TNP00305; Alapav (TN); Albatran (TN); Artegodan (TN); Cardiospan (TN); Cardioverina (TN); Cepaverin (TN); Cerebid (TN); Cerespan (TN); Delapav (TN); Dicertan (TN); Dilaves (TN); Dispamil (TN); Drapavel (TN); Durapav (TN); Dynovas (TN); Forpaven (TN); Houde (TN); Mesotina (TN); Myobid (TN); Opdensit (TN); Optenyl (TN); Pameion (TN); Pamelon (TN); Panergon (TN); Papacon (TN); Papalease (TN); Papanerin-hcl; Papaversan (TN); Pavabid (TN); Pavacap (TN); Pavacen (TN); Pavadel (TN); Pavadyl (TN); Pavagen (TN); Pavakey (TN); Pavased (TN); Pavatest (TN); Paverina (TN); Paverolan (TN); Paveron (TN); Pavnell (TN); Qua bid (TN); Ro-Papav; Therapav (TN); Vasal (TN); Vaso-Pav; Vasospan (TN); Papanerin-hcl (TN); Papaverin-Hamelin (TN); Papital TR; Paptial TR; Ro-Papav (TN); Spasmo-Nit (TN); Vaso-Pav (TN); Pap-Kaps-150 (TN); Papital TR (TN); Paptial TR (TN); Isoquinoline,6,7-dimethoxy-1-veratryl-(8CI); Isoquinoline, 6,7-dimethoxy-1-veratryl-(8Cl); 1-[(3,4-Dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; 1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline; 4-[(6,7-Dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; 1-(3,4-DIMETHOXYBENZYL)-6,7-DIMETHOXYISOQUINOLINE
Indication
Disease Entry ICD 11 Status REF
Brain ischaemia 8B1Z Approved [1]
Spasm MB47.3 Approved [2]
Peripheral vascular disease BD4Z Investigative [3]
Therapeutic Class
Vasodilator Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 339.4
Logarithm of the Partition Coefficient (xlogp) 3.9
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Clearance
The drug present in the plasma can be removed from the body at the rate of 11 mL/min/kg [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 0.5 - 2 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 25.2554 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.073% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1 L/kg [4]
Chemical Identifiers
Formula
C20H21NO4
IUPAC Name
1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline
Canonical SMILES
COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC
InChI
InChI=1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3
InChIKey
XQYZDYMELSJDRZ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4680
ChEBI ID
CHEBI:28241
CAS Number
58-74-2
DrugBank ID
DB01113
TTD ID
D0NJ3V
VARIDT ID
DR00967
INTEDE ID
DR2299
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 4D (PDE4D) TTSKMI8 PDE4D_HUMAN Inhibitor [6]
Phosphodiesterase 5A (PDE5A) TTJ0IQB PDE5A_HUMAN Inhibitor [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Gene/Protein Processing [8]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Gene/Protein Processing [9]
Cystic fibrosis transmembrane conductance regulator (CFTR) OT6B22QH CFTR_HUMAN Gene/Protein Processing [10]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Gene/Protein Processing [11]
Hepcidin (HAMP) OT607RBL HEPC_HUMAN Gene/Protein Processing [12]
Transmembrane protease serine 2 (TMPRSS2) OTN44YQ5 TMPS2_HUMAN Gene/Protein Processing [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Brain ischaemia
ICD Disease Classification 8B1Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Phosphodiesterase 5A (PDE5A) DTT PDE5A 1.60E-01 -0.25 -0.99
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Papaverine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Papaverine and Ivosidenib. Acute myeloid leukaemia [2A60] [13]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Papaverine and Midostaurin. Acute myeloid leukaemia [2A60] [13]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Papaverine and Idarubicin. Acute myeloid leukaemia [2A60] [13]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Papaverine and Arn-509. Acute myeloid leukaemia [2A60] [13]
Gilteritinib DMTI0ZO Major Increased risk of prolong QT interval by the combination of Papaverine and Gilteritinib. Acute myeloid leukaemia [2A60] [13]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Papaverine and Oliceridine. Acute pain [MG31] [14]
Ivabradine DM0L594 Major Increased risk of prolong QT interval by the combination of Papaverine and Ivabradine. Angina pectoris [BA40] [13]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Papaverine and Dronedarone. Angina pectoris [BA40] [13]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Papaverine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [13]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Papaverine and Cilostazol. Arterial occlusive disease [BD40] [13]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Papaverine and Posaconazole. Aspergillosis [1F20] [13]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Papaverine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [13]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Papaverine and Desipramine. Attention deficit hyperactivity disorder [6A05] [13]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Papaverine and Ofloxacin. Bacterial infection [1A00-1C4Z] [13]
Clarithromycin DM4M1SG Major Increased risk of prolong QT interval by the combination of Papaverine and Clarithromycin. Bacterial infection [1A00-1C4Z] [13]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Papaverine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [13]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Papaverine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [13]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Papaverine and Levofloxacin. Bacterial infection [1A00-1C4Z] [13]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Papaverine and Retigabine. Behcet disease [4A62] [13]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Papaverine and Cariprazine. Bipolar disorder [6A60] [15]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Papaverine and Eribulin. Breast cancer [2C60-2C6Y] [13]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Papaverine and Lapatinib. Breast cancer [2C60-2C6Y] [13]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Papaverine and Bosutinib. Breast cancer [2C60-2C6Y] [13]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Papaverine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [13]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Papaverine and Halothane. Corneal disease [9A76-9A78] [13]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Papaverine and Sevoflurane. Corneal disease [9A76-9A78] [13]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Papaverine and Probucol. Coronary atherosclerosis [BA80] [13]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Papaverine and Pasireotide. Cushing syndrome [5A70] [13]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Papaverine and Osilodrostat. Cushing syndrome [5A70] [13]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Papaverine and Isocarboxazid. Depression [6A70-6A7Z] [16]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Papaverine and Escitalopram. Depression [6A70-6A7Z] [13]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Papaverine and OPC-34712. Depression [6A70-6A7Z] [15]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Papaverine and Clomipramine. Depression [6A70-6A7Z] [13]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Papaverine and Doxepin. Depression [6A70-6A7Z] [13]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Papaverine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [13]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Papaverine and Deutetrabenazine. Dystonic disorder [8A02] [13]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Papaverine and Ingrezza. Dystonic disorder [8A02] [13]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Papaverine and Solifenacin. Functional bladder disorder [GC50] [13]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Papaverine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [13]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Papaverine and Procarbazine. Hodgkin lymphoma [2B30] [16]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Papaverine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [13]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Papaverine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [13]
Lopinavir DMITQS0 Major Increased risk of prolong QT interval by the combination of Papaverine and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [13]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Papaverine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [13]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Papaverine and ITI-007. Insomnia [7A00-7A0Z] [15]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Papaverine and Crizotinib. Lung cancer [2C25] [13]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Papaverine and Osimertinib. Lung cancer [2C25] [13]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Papaverine and Selpercatinib. Lung cancer [2C25] [13]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Papaverine and Lumefantrine. Malaria [1F40-1F45] [13]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Papaverine and Halofantrine. Malaria [1F40-1F45] [13]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Papaverine and Hydroxychloroquine. Malaria [1F40-1F45] [13]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Papaverine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [13]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Papaverine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [13]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Papaverine and Vemurafenib. Melanoma [2C30] [13]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Papaverine and Panobinostat. Multiple myeloma [2A83] [13]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Papaverine and Siponimod. Multiple sclerosis [8A40] [17]
Fingolimod DM5JVAN Major Increased risk of prolong QT interval by the combination of Papaverine and Fingolimod. Multiple sclerosis [8A40] [13]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Papaverine and Ozanimod. Multiple sclerosis [8A40] [18]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Papaverine and Romidepsin. Mycosis fungoides [2B01] [13]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Papaverine and Nilotinib. Myeloproliferative neoplasm [2A20] [13]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Papaverine and Dasatinib. Myeloproliferative neoplasm [2A20] [13]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Papaverine and Entrectinib. Non-small cell lung cancer [2C25] [13]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Papaverine and Levomethadyl Acetate. Opioid use disorder [6C43] [13]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Papaverine and Lofexidine. Opioid use disorder [6C43] [13]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Papaverine and Rucaparib. Ovarian cancer [2C73] [13]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Papaverine and Triclabendazole. Parasitic worm infestation [1F90] [13]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Papaverine and Safinamide. Parkinsonism [8A00] [16]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Papaverine and Rasagiline. Parkinsonism [8A00] [16]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Papaverine and Pimavanserin. Parkinsonism [8A00] [13]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Papaverine and Macimorelin. Pituitary gland disorder [5A60-5A61] [13]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Papaverine and Lefamulin. Pneumonia [CA40] [13]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Papaverine and Degarelix. Prostate cancer [2C82] [13]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Papaverine and Enzalutamide. Prostate cancer [2C82] [13]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Papaverine and Relugolix. Prostate cancer [2C82] [13]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Papaverine and Levomepromazine. Psychotic disorder [6A20-6A25] [15]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Papaverine and Quetiapine. Schizophrenia [6A20] [13]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Papaverine and Aripiprazole. Schizophrenia [6A20] [15]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Papaverine and Iloperidone. Schizophrenia [6A20] [13]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Papaverine and Paliperidone. Schizophrenia [6A20] [15]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Papaverine and Molindone. Schizophrenia [6A20] [15]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Papaverine and Amisulpride. Schizophrenia [6A20] [13]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Papaverine and Asenapine. Schizophrenia [6A20] [13]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Papaverine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [13]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Papaverine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [13]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Papaverine and Pitolisant. Somnolence [MG42] [13]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Papaverine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [13]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Papaverine and Lenvatinib. Thyroid cancer [2D10] [13]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Papaverine and Cabozantinib. Thyroid cancer [2D10] [13]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Papaverine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [13]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Papaverine and Propafenone. Ventricular tachyarrhythmia [BC71] [13]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Papaverine and Flecainide. Ventricular tachyarrhythmia [BC71] [13]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Papaverine and Amiodarone. Ventricular tachyarrhythmia [BC71] [13]
⏷ Show the Full List of 92 DDI Information of This Drug

References

1 Intra-Arterial Papaverine-Hydrochloride and Transluminal Balloon Angioplasty for Neurointerventional Management of Delayed-Onset Post-Aneurysmal Subarachnoid Hemorrhage Vasospasm. World Neurosurg. 2018 Nov;119:e301-e312.
2 Drug information of Papaverine, 2008. eduDrugs.
3 Aetiopathogenesis and management of impotence in diabetic males: four years experience from a combined clinic. Diabet Med. 1995 Jan;12(1):77-82.
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
7 Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8.
8 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
9 Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem Pharmacol. 2012 Jun 15;83(12):1674-81. doi: 10.1016/j.bcp.2012.02.027. Epub 2012 Mar 7.
10 Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):410-8. doi: 10.1165/rcmb.2002-0247OC. Epub 2003 Apr 24.
11 A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
12 A HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression. Exp Hematol. 2015 May;43(5):404-413.e5. doi: 10.1016/j.exphem.2015.01.005. Epub 2015 Jan 26.
13 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
14 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
15 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
16 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
17 Cerner Multum, Inc. "Australian Product Information.".
18 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.